EIF4E2 is a translation initiation factor that functions as a selective translational repressor competing with the canonical cap-binding protein eIF4E 1. It binds to the 5' mRNA cap structure and negatively regulates translation initiation, particularly under stress conditions 2. During ribosomal collisions induced by aberrant mRNAs, EDF1 recruits EIF4E2 and GIGYF2 to collided ribosomes, establishing a negative-feedback loop that prevents translation of defective mRNAs 2. EIF4E2 interacts with GSK3β to regulate its kinase activity, a mechanism relevant to stress responses and cardiovascular disease 34. In viral infection, SARS-CoV-2 nsp2 enhances GIGYF2 binding to EIF4E2, increasing repression of antiviral immune genes including IFNB1 [UniProt annotation]. Paradoxically, EIF4E2 also promotes selective translation of specific mRNAs under hypoxia, including collagen-modifying enzymes PLOD2 and P4HA1 in cancer cells 5. METTL16 interaction with EIF4E2 prevents its recruitment to 5' cap structures, promoting eIF4E-mediated cap recognition and selective oncogene translation in lung cancer 1. EIF4E2 mediates hypoxia-induced translation of cancer-promoting genes and stabilizes chemokine mRNAs in immunotherapy contexts 67. As an early-stage dependency factor for SARS-CoV-2 infection, EIF4E2 represents a potential therapeutic target 8.